Registration Number
0219U000831,
0116U002161
, R & D reports
Title
Determine the features of the immunity system in patients with toxic goiter and thyroid cancinoma under radioiodine treatment
popup.stage_title
Head
Tronko Mykola Dmytrovych; Zamotayeva Galyna Anatolijivna,
Registration Date
28-02-2019
Organization
State institution "V.P. Komisarenko Institute of Endocrynology and Metabolism of the National Academy of Medical Science of Ukraine"
popup.description2
Object of the study: State of the immune and hematological systems in patients with diffuse toxic goiter and differentiated thyroid cancer after radioiodine treatment. Purpose: Estimation of hematological and immunological consequences of radioiodine therapy in patients with toxic goiter and thyroid cancer, determination of their features and mechanisms of formation. Methods: radiometric, spectrophotometric, immunological, flow cytofluorimetry. Theoretical and practical results. A detailed dynamic study of the effect of radioactive iodine on the leukocyte composition and phenotype of peripheral blood lymphocytes, as well as the factors of innate immunity in patients with diffuse toxic goiter and thyroid cancer, was performed. We evaluated the immune-hematological consequences of radioiodine therapy with recombinant human thyroid-stimulating hormone (rhTSH, “Thyrogen”) versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer patients. Short-term and long-term effects of radioiodine therapy have been determined. New data on the features and mechanisms of the formation of the immune and hematological disorders under radioiodine therapy were obtained. It was found that significant disorders in the immune system typical for the autoimmune process in patients with diffuse toxic goiter already before radioiodine therapy. Despite a significant difference in the activity of iodine-131, which was used to treat patients with thyroid cancer and diffuse toxic goiter, the main trends of changes in immune-hematological parameters were similar. However, the degree of disorders in the immunity system of patients with toxic goiter was not so pronounced, and the restoration of disturbed indicators was occurred earlier. Conducting a comparative assessment of immunological and hematological parameters in patients with thyroid cancer for exogenous and endogenous stimulation of thyroid stimulating hormone reviled that patients who have undergone radioiodine therapy by withdrawal of L-thyroxine demonstrated more significant immunological changes that may be due with a long-term state of hypothyroidism. Under the conditions of treatment with radioiodine, using "Thyrogen", the degree of immunological disorders was lower, and their recovering was faster, which, obviously, is due to a decrease in the radiation exposure of extra-thyroid tissues. The results obtained are a significant argument in favor of using rhTSH in the radioiodine therapy. Novelty. A method for predicting the risk of developing hematologic diseases in patients with thyroid cancer treated with radioactive iodine has been developed and patented. Advantage over existing analogs. The use of the proposed method provides increased informativeness of the determination of the effect of iodine radionuclides on hemopoiesis, the changes of which will make it possible to predict the risks of hematological diseases. Field of use: radiation biology, radiotherapy, oncology.
Product Description
popup.authors
Замотаєва Галина Анатоліївна
Захарченко Тамара Федорівна
Калініченко Олена Віталіївна
Степура Наталія Миколаївна
Тронько Микола Дмитрович
popup.nrat_date
2020-04-02
